A Phase 1 interventional study of [14C] MT1013/MT1013 Injection in Hemodialysis Subjects With Secondary Hyperparathyroidism, sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Hyperparathyroidism, Secondary with a site in China — 4 open to participants now, 5 under way, 1 of them phase 3. Hyperparathyroidism, Secondary · China.
Among the 23 studies in Hyperparathyroidism, Secondary with a site in China, this one is the 17th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 1, and was the 22nd registered.
188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.
Browse Hyperparathyroidism, Secondary studies →4 of the 23 studies in Hyperparathyroidism, Secondary with a site in China are open now. Recruiting first, the newest first:
Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18+
Shaanxi Micot Technology Limited Company · Sites in China
Ages 18+
The Second Hospital of Nanjing Medical University · Sites in China
Ages 18–70
Limeng Chen · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2025.
This study's enrollment of 6 is below the median of 62 across 146 interventional studies indexed under Hyperparathyroidism, Secondary.
Median enrollment 158 across the 18 interventional studies, 192 across the 5 observational. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 23 have an industry lead sponsor. The 10 most frequent:
Shaanxi Micot Pharmaceutical Technology Co., Ltd. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Shaanxi Micot Pharmaceutical Technology Co., Ltd. has 4 studies filed under Hyperparathyroidism, Secondary — fewer than ten, so there is no comparison to draw.
1 of the studies in Hyperparathyroidism, Secondary with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07122401Phase 3Shaanxi Micot Pharmaceutical Technology Co., Ltd.Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism | 2026-11-26 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Hyperparathyroidism, Secondary with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of [14C] MT1013.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: [14C] MT1013/MT1013 Injection
\[14C\] MT1013/MT1013 Injection
Cumulative excretion of radioactivity
Time frame: Day 1 to Day 91.
Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)
Time frame: Day 1 to Day 91.
Adverse Events (AEs)
Time frame: About 13 weeks.
Serious adverse Events (SAEs)
Time frame: About 13 weeks.
Ran from Nov 2025 to primary completion in May 2026, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperparathyroidism, Secondary →
Shaanxi Micot Pharmaceutical Technology Co., Ltd.